RenovoRx Corporation (RNXT): Broker Consensus Forecast

Symbol and logo of brand RenovoRx Inc (RNXT)

RenovoRx, Inc. (RNXT) bases its business on creating targeted delivery systems for oncology drugs, where high margins are achieved through low-cost consumable production against fixed development costs. This price chart on GURU.Markets, where the indicator stands at 7.15, illustrates the company's dynamics. RenovoRx, Inc. (RNXT) minimizes risks by implementing precision targeting methods for neoplasms, which significantly enhances the efficacy of therapy for complex pathologies.

RNXT (RenovoRx Corporation) Consensus Target history from 07/04/2022 to 11/11/2026

Analytical breakdowns for RenovoRx Corp (RNXT)

- share price and consensus valuation forecast:
Price Performance Chart renovorx.com|RNXT - Price Target Chart
- stock exchange capitalization data:
Market Capitalization RenovoRx Corp|RNXT - Real Price to Acquire Entire Company
- business book valuation details:
Equity per Share RenovoRx|RNXT - Company Net Assets|Market Cap to Book Value Multiple renovorx.com|RNXT - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio RenovoRx, Inc.|RNXT - Long-Term Debt to Capital|Short-Term Debt to Capital RenovoRx Corporation|RNXT - Company Debts|Debt to Book Value Ratio RenovoRx Corp|RNXT - Company Long-Term Debts|Company Current Liabilities RenovoRx|Immediate Liquidity renovorx.com
- net income and valuation multiples indicators:
RNXT - Company Net Income|Expected Net Income RenovoRx, Inc.|RNXT - Price to Earnings Ratio|Future Price to Earnings Multiple RenovoRx Inc|RNXT - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio RenovoRx Corp|RNXT - Operating profit before deduction of amortization|Earnings per share for the last four quarters RenovoRx|RNXT - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months renovorx.com|RNXT - Earnings per share growth in current year|Expected earnings per share growth for next year RenovoRx, Inc.
Fundamental company analysis:renovorx.com (RNXT)
Original product of RenovoRx Corp

For RenovoRx, Inc., which has minimized capital risks by outsourcing the production of targeted therapy systems, this indicator reflects the dynamics of market expectations regarding the business valuation. By analyzing the current market consensus target, an investor can see the average target price from experts, which is adjusted under the influence of macroeconomic liquidity and inflation, determining the asset's degree of overvaluation or its growth potential.

Competing companies

TLSI (trisaluslifesci.com) - Fair Value Consensus|Price Target Chart PharmaCyte Biotech, Inc. PMCB